Disitamab vedotin
A monoclonal antibody used in cancer treatment
| Disitamab vedotin | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Disitamab vedotin is a monoclonal antibody used in the treatment of certain types of cancer. It is an antibody-drug conjugate (ADC) that targets the HER2 receptor, which is overexpressed in some cancer cells. Disitamab vedotin is designed to deliver a cytotoxic agent directly to the cancer cells, thereby minimizing damage to normal cells.
Mechanism of Action[edit]
Disitamab vedotin works by targeting the HER2 receptor, a protein that is overexpressed in various cancers, including breast cancer and gastric cancer. The drug is an ADC, which means it consists of a monoclonal antibody linked to a cytotoxic agent. The monoclonal antibody part of disitamab vedotin binds to the HER2 receptor on the surface of cancer cells. Once bound, the entire complex is internalized by the cell, where the cytotoxic agent is released, leading to cell death.
Development and Approval[edit]
Disitamab vedotin was developed by RemeGen, a biotechnology company based in China. It was approved for medical use in China in 2021 for the treatment of HER2-positive gastric cancer. The drug is currently undergoing clinical trials for other types of cancer, including urothelial carcinoma and breast cancer.
Clinical Trials[edit]
Clinical trials have shown that disitamab vedotin is effective in shrinking tumors in patients with HER2-positive cancers. In particular, it has shown promise in patients who have not responded to other HER2-targeted therapies. Ongoing trials are investigating its efficacy in combination with other cancer treatments.
Side Effects[edit]
The side effects of disitamab vedotin are similar to those of other ADCs. Common side effects include fatigue, nausea, and peripheral neuropathy. More serious side effects can include neutropenia and liver toxicity. Patients receiving disitamab vedotin are monitored closely for these adverse effects.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
